

Delivering & developing new treatments for mental health & neurological conditions

ASX Announcement | 29 February 2024

Emyria Half Year Results FY2024

Emyria Limited (ASX: EMD) ("Emyria", or the "Company") delivering and developing new treatments for mental health and select neurological conditions, is pleased to share its Financial Report and a summary of progress for the half year ended December 31, 2023

TREATMENT DELIVERY HIGHLIGHTS

Acquired Pax Centre enhancing clinical services and mental health care capabilities.

Grew clinical billings for the period to over \$2m (compared to \$638 in previous period).

Secured ethics endorsements for Emyria's MDMA-Assisted Therapy model and related Authorised Prescriber approval applications (since obtained).

Commenced dosing in our MDMA-assisted therapy trial, supported by successful importation of required drug supply from Canada.

TREATMENT DEVELOPMENT HIGHLIGHTS

All intellectual property claims related to first patent family of MDMA analogues deemed 'novel' and 'inventive' in international review, strengthening our position for expedited National Phase approvals and highlighting the potential of our novel library.

Achieved a critical milestone in the NIH's fully-funded Preclinical Screening Program for Pain with our high-dose CBD capsules (RX7/9), showcasing their therapeutic potential. Program is now advanced, and fully-funded, to Tier 2 screening.

Recognised an impairment of \$6.9 million for RX5 while program remains on hold.

CORPORATE HIGHLIGHTS

Implemented Board changes to support the strategic direction of our mental health innovation priorities aligned with our therapeutic and research goals.

Cash position of \$1.97 million, with a significant R&D tax refund of \$2.53 million received in January 2024.



EMYRIA'S STRATEGIC FOCUS FOR THE PERIOD

Following the TGA rescheduling of MDMA and psilocybin on July 1st, the Company moved to accelerate the Company's programs in psychedelic-assisted therapy, in particular the Company's lead MDMA-Assisted Therapy for PTSD program.

Consequently, the Company prioritised initiatives that aligned with the vision to become a global leader in the delivery and development of psychedelic-assisted therapies, driven by the potential for significant positive patient impact and future value creation.

Key moves included acquiring the Pax Centre - a leader in psychological trauma care, efficiently securing key regulatory approvals for Emyria's unique care models, Authorised Prescriber applications and drug importation and also enhancing the Board with experts skilled in scaling tech-supported clinical services.

The Company is committed to building a business that is primed for long-term growth and difficult for competitors to replicate.

OUTLOOK

With all essential approvals obtained, alongside fit-for-purpose facilities and a collaborative, trained clinical team, the Company is dedicated to demonstrating the commercial viability and clinical significance of its distinct approach to mental health care. The Company's priority is to evaluate the Real-World efficacy of its unique MDMA-Assisted Therapy Model for treating PTSD – a condition impacting over 1m Australians. Following this, the Company aims to secure payer support and expand the successful delivery model on a national and then global scale.

The Group will concentrate on progressing its business interests, which include:

- **Expand clinical services** by building on the momentum of integrating the Pax Centre, we aim to broaden our service offerings to address unmet medical needs, drive revenue growth and improve patient care.
- **Scale care delivery programs** through organic growth and select partnerships while leveraging our clinical data to engage major Health Payers. Our goal is to enhance access to specialised mental health care and support for a broader patient base across Australia.
- Capturing ethically sourced, high-quality clinical data with patients to transform the way novel therapies are understood and researched.
- Advance proprietary drug development programs with world-leading institutions like the University of Western Australia (UWA) and the National institute of Health (NIH) utilising third-party funding support where possible.
- Optimise Intellectual Property and financials: With a favourable review of our MDMA analogue IP claims and growing revenues, we're strategically advancing our high-potential projects while maintaining financial health and shareholder value.

This release has been approved by the Managing Director of Emyria.



emyria.com

Emyria Limited is focused on developing and delivering new treatments for mental health and select neurological conditions through through an integrated model of direct clinical services and drug development:



Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like MDMA-assisted therapy for PTSD¹



Emyria Data: Robust and ethically-sourced Real-World Data gathered with patients and used to improve Emyria's unique therapy and drug development programs.

Emyria's Pipeline: One of the world's largest libraries of unique MDMA-like compounds developed in partnership with the University of Western Australia seeking new psychedelic-assisted therapies and treatments for neurological diseases as well as highly potent dose forms of Ultra-Pure CBD seeking registration for a range of mental health and neuroscience indications.

FOR FURTHER INFORMATION

Managing Director **Michael Winlo** +61 (0) 8 6559 2800 mwinlo@emyria.com **Media Contact Haley Chartres** +61 (0) 423 139 163 haley@hck.digital **Corporate Advisor Sufian Ahmed** +61 (0) 412 316 162 info@62capital.com.au

EMYRIA'S INTERACTIVE INVESTOR HUB

Investorhub.emyria.com Interact with Emyria's announcements and updates by asking questions and comments, which our team can respond to where possible.



CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.